Nymox Pharmaceutical Corp Buchwert je Aktie
Was ist das Buchwert je Aktie von Nymox Pharmaceutical Corp?
Buchwert je Aktie von Nymox Pharmaceutical Corp ist 0.01
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Nymox Pharmaceutical Corp
Was macht Nymox Pharmaceutical Corp?
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.
Unternehmen mit buchwert je aktie ähnlich Nymox Pharmaceutical Corp
- Sulliden Mining Capital hat Buchwert je Aktie von 0.01
- Metro Mining hat Buchwert je Aktie von 0.01
- Code Agriculture () hat Buchwert je Aktie von 0.01
- Avenira hat Buchwert je Aktie von 0.01
- Voyageur Pharmaceuticals hat Buchwert je Aktie von 0.01
- KORE Mining hat Buchwert je Aktie von 0.01
- Nymox Pharmaceutical Corp hat Buchwert je Aktie von 0.01
- Battery Minerals hat Buchwert je Aktie von 0.01
- Metalsearch hat Buchwert je Aktie von 0.01
- Versarien plc hat Buchwert je Aktie von 0.01
- Fuse Cobalt Inc hat Buchwert je Aktie von 0.01
- Resolve Ventures hat Buchwert je Aktie von 0.01
- WLS hat Buchwert je Aktie von 0.01